

New Hampshire AIDS Drug Assistance Program

Prior Authorization/Non-Preferred Drug Approval Form

GLP-1 Agonists for Diabetes

DATE OF MEDICATION REQUEST: /	/												
SECTION I: PATIENT INFORMATION AND MEDICATIO	ON REQUE	STED)										
LAST NAME:	FIRS	FIRST NAME:											
MEDICAID ID NUMBER:	DAT	DATE OF BIRTH:											
			_			_]		
GENDER: Male Female			1							1	J		
Drug Name:		Strength:											
Dosing Directions:			Length of Therapy:										
SECTION II: PRESCRIBER INFORMATION													
LAST NAME:		ME:	1E:										
SPECIALTY:	NPII	NUM	BER:										
PHONE NUMBER:	FAX	NUM	BER:								_		
				– [_					
SECTION III: CLINICAL HISTORY													
1. Does the patient have a diagnosis of a type 2 diab	oetes mell	itus (a	adjun	ct to	diet	and	exerc	cise)?)	Y	es 🗌	No	
If no, provide diagnosis:													
2. Has the patient had prior use of metformin or a metformin-containing product?] No					
If yes, provide treatment and dates:													
If no, provide contraindication or adverse effect:													
3. Are there any other comments, diagnoses, or mean review?	dication ti	rials t	hat w	ould	be ir	npor	tant	to th	is	Y	es 🗌] No	

Provide details:

(Form continued on next page.)



New Hampshire AIDS Drug Assistance I Prior Authorization/Non-Preferred Dru	•
GLP-1 Agonist for Diabetes DATE OF MEDICATION REQUEST: /	/
PATIENT LAST NAME:	PATIENT FIRST NAME:
SECTION IV: NON-PREFERRED DRUG APPROVAL CRITERI	A
Chapter 188 of the Laws of 2004 requires that Medicaid of necessity by the prescribing physician. Chapter 188 require on the following criteria.	only cover non-preferred drugs upon a finding of medical res that you base your determination of medical necessity
Allergic reaction. Describe reaction:	
Drug-to-drug interaction. Describe reaction :	
Previous episode of an unacceptable side effect or th	erapeutic failure. Provide clinical information:
Clinical contraindication, co-morbidity, or unique patie Provide clinical information:	ent circumstance as a contraindication to a preferred drug.
Age specific indications. Provide patient age and exp	lain:
Unique clinical indication supported by FDA approval reference:	or peer reviewed literature. Explain and provide a
Unacceptable clinical risk associated with therapeution	change. Please explain:
I certify that the information provided is accurate and co that any falsification, omission, or concealment of mater	
PRESCRIBER'S SIGNATURE:	DATE:

